Chen G, Qiu H, Ke SD, Hu SM, Yu SY, Zou SQ. Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling. World J Gastroenterol 2013; 19(16): 2481-2491 [PMID: 23674849 DOI: 10.3748/wjg.v19.i16.2481]
Corresponding Author of This Article
Dr. Shao-Ming Hu, Integration Traditional Chinese Medicine and Western Medicine Department, TongJi Hospital, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan 430030, Hubei Province, China. smhu@tjh.tjmu.edu.cn
Research Domain of This Article
Oncology
Article-Type of This Article
Original Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Apr 28, 2013; 19(16): 2481-2491 Published online Apr 28, 2013. doi: 10.3748/wjg.v19.i16.2481
Emodin regulating excision repair cross-complementation group 1 through fibroblast growth factor receptor 2 signaling
Gang Chen, Hong Qiu, Shan-Dong Ke, Shao-Ming Hu, Shi-Ying Yu, Sheng-Quan Zou
Gang Chen, Shan-Dong Ke, Shao-Ming Hu, Integration Traditional Chinese Medicine and Western Medicine Department, TongJi Hospital, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Hong Qiu, Shi-Ying Yu, Department of Oncology, TongJi Hospital, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Sheng-Quan Zou, Department of Surgery, TongJi Hospital, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China
Author contributions: Chen G and Ke SD performed the majority of experiments; Qiu H and Zou SQ provided financial support for this work; Chen G, Qiu H, Hu SM and Yu SY designed the study and wrote the manuscript.
Supported by National Natural Sciences Foundation of China, No. 81001067; the Ministry of Science and Technology International Cooperation Project, No. 2010DFA31870; and the AstraZeneca Special Research Foundation for Targeted Therapy of the Wu Jieping Medical Foundation, No. 320.6700.09068
Correspondence to: Dr. Shao-Ming Hu, Integration Traditional Chinese Medicine and Western Medicine Department, TongJi Hospital, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Qiaokou District, Wuhan 430030, Hubei Province, China. smhu@tjh.tjmu.edu.cn
Telephone: +86-27-83663532 Fax: +86-27-83663445
Received: October 3, 2012 Revised: March 15, 2013 Accepted: March 21, 2013 Published online: April 28, 2013 Processing time: 210 Days and 11.3 Hours
Core Tip
Core tip: In this study, our results indicated that emodin could significantly enhance the DNA damage caused by oxaliplatin (OXA) and induce OXA resistance reversal in HepG2/OXA cells. The molecular mechanism for this phenomenon is mediated by the inhibition of excision repair cross-complementing gene 1 expression by the fibroblast growth factor receptor 2/phosphorylated extracellular signal-regulated kinase 1/2 signaling pathway. The results for the reversal of platinum resistance by emodin and the emodin-based enhancement of the efficacy of platinum-based chemotherapy in hepatocellular carcinoma may provide an experimental basis for the further development and application of emodin in the reversal of platinum drug resistance in other types of malignant tumors.
